For results that fall close to the cutoff ranges, physicians can now speak directly with the ASPiRA Labs’ Director, Dr. Fritsche. We hope this clinical discussion will help you better understand OVA1 (MIA) scoring and assess the best treatment plan for your patients.
OVA1 Testing Resources
OVA1 (MIA): Understanding Results
Incorporate ultrasound into your OVA1 result interpretation.
Combining OVA1 (MIA) with powerful tools like an ultrasound can aid in the detection of ovarian cancer. According to a study by Goodrich et al., imaging and the OVA1 (MIA) score work together to better identify patients at higher risk of malignancy. For more details, call clinical support: 1-844-ASPiRA1.
In the prospective study, Bristow, et al. published a histogram showing the observed risk of malignancy associated with respective OVA1 (MIA) scores for premenopausal and postmenopausal women5:
Risk of malignancy was reported as below 1.4% for premenopausal women and 3.3% for postmenopausal women.
Higher risk of malignancy – see graph for representative data from published clinical trial below.
Test Performance Measures
Learn about the terminology and performance measures to determine the accuracy of a diagnostic test:
High sensitivity is often determined as the most critical measure of a test because it minimizes the number of patients with the disease that are missed. A highly sensitivity test is generally associated with a strong negative predictive value; this gives providers confidence that a negative test result likely suggests a patient is truly without the disease.
Sensitivity: The percent of patients with a malignant mass who had a positive test result
Specificity: The percent of patients with a benign mass who had a negative test result
Negative predictive value: The percent of patients with a negative test result who had a benign mass
Positive predictive value: The percent of patients with a positive test result who had a malignant mass
False positive: The percent of patients with a positive test result who had a benign mass
False negative: The percent of patients with a negative test result who had a malignant mass
- Carney ME, et al., Gynecol Oncol. 2002 Jan;84(1):36-42.
- Earle CC, et al., J Natl Cancer Inst. 2006 Feb 1;98(3):172-80
- Ueland, FR et al., Gynecol Oncol. 2005 Nov;99(2):400-3
- Goodrich ST, et al., Am J Obstet Gynecol. 2014 Jul;211(1):65.e1-65.e11
- Bristow RE, et al., Gynecol Oncol. 2013;128:252-259
- Timmerman D, et al., Ultrasound Obstet Gynecol 1999;13:11–16
- Levine D, et al., Ultrasound Q. 2010 Sep;26(3):121-31.
- Ueland FR, et al., Obstet Gynecol. 2011;117(6):1289-1297
- Longoria TC, et al., Am J Obstet Gynecol. 2014 Jan;210(1):78.e1-9
- Moss EL, et al., J Clin Pathol. 2005 Mar; 58(3): 308–312.
- Petignat P, et al., Eur J Cancer. 2000 Oct;36(15):1933-7.
- Bristow RE, et al., Am J Obstet Gynecol. 2013 Dec;209(6):581.e1-8
- American Congress of Obstetricians and Gynecologists, Practice Bulletin 174; 2016 Nov